A Growing Threat to Public Health
The Drug Regulatory Authority of Pakistan (DRAP) has sounded the alarm over counterfeit medicines being sold across Punjab and Gilgit-Baltistan. These fake pharmaceuticals are being marketed under the names of well-known local and international brands, posing serious risks to public health.
What’s Inside the Counterfeit Batches?
According to DRAP’s official alert, the counterfeit drugs are being falsely promoted as treatments for a wide range of conditions including:
- Fever and body pain
- Throat and chest infections
- Gynecological issues
- Digestive disorders
- Fungal diseases
- Neuropathy
These fake medicines were identified following reports from provincial health departments and subsequent testing by certified drug laboratories.
List of Counterfeit Medicines Identified
DRAP has released a list of specific batches found to be counterfeit:
- Brexin Tablets – Batch No. 1192087 (Pain relief)
- Zetro 500mg Tablets – Batch No. F18031 (Throat infections)
- Augmentin 625mg Tablets – Batch No. 7F4W (Chest infections)
- Tonoflex-P Tablets – Batch No. KFM145 (Pain relief)
- Feston 10mg Tablets – Batch No. 41160 (Gynecological conditions)
- Gabica 300mg Capsules – Batch No. 403C27 (Neuropathy)
- Amcomox Capsules – Batch No. 08 (Throat infections)
- OmniDol N-Uk Tablets – Batch No. 1220 (Fever and body pain)
DRAP’s Response and Public Advisory
DRAP has traced a network involved in the production and distribution of these counterfeit drugs. In response, the authority has issued a rapid alert to pharmacies and the general public, urging everyone to avoid purchasing medicines from unauthorized sources.
Consumers are advised to:
- Check packaging and batch numbers carefully
- Purchase medicines only from licensed pharmacies
- Report any suspicious products to DRAP immediately
Why This Matters
Counterfeit medicines not only fail to treat the intended conditions but can also cause harmful side effects. DRAP’s swift action aims to protect citizens from these dangerous products and ensure the integrity of Pakistan’s pharmaceutical supply chain.
Stay Informed, Stay Safe
As the crackdown continues, DRAP encourages the public to remain vigilant and informed. Ensuring medicine authenticity is a shared responsibility—and a crucial step toward safeguarding public health in Pakistan.